Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
AddendumFull Access

ADDENDUM

Published Online:1 Dec 2015https://doi.org/10.1176/appi.ajp.2015.17212Addendum

Additional analysis found a trend significance in QTc by 8.8 msec in the ziprasidone-tested group and a significant increase in weight gain of 3.5 kg in the ziprasidone-treated group versus 1.0 kg on placebo. Further information on these and other laboratory parameters is available from Dr. Papakostas ().